Appointments at Protalix, Pevion, NeoStem and ProStraken – People on the move
Protalix BioTherapeutics has appointed Tzvi Palash as chief operating officer. In this newly created role Palash will oversee manufacturing. Palash has more than 25 years of experience working at companies including ColBar LifeScience, CTS, Teva and Interpharm Laboratories.
Marc Tessier-Lavigne is leaving Genentech to become president of the Rockefeller University. Tessier-Lavigne joined Genentech in 2003 and was promoted to executive vice president (EVP) for research and chief scientific officer in 2009.
Univar has appointed Steve Block as VP and president of ChemPoint.com.
Evert Kueppers has been named as CEO of Pevion Biotech, succeeding Thomas Stauffer. Kueppers has previously worked at Pieris AG, IDEA AG, BASF Pharma and AT Kearney.
Intellect Neurosciences has hired Giora Feuerstein as a consultant. Feuerstein is the former head of discovery translational medicine at Wyeth and Pfizer.
Wilson Totten has resigned as CEO and as a director of ProStraken. Peter Allen has been appointed as acting CEO. Totten resigned after news of regulatory delays and that closure of a contractor’s factory will impact profits.
Curemark has promoted James Szigethy to the position of director of new product development. Szigethy joined Curemark in 2007 having previously worked at Wal-Mart.
Craig Eagle has been elected to the board of directors at Regenicin. Eagle is VP of strategic alliances and partnerships for the oncology business unit at Pfizer.
NeoStem has named Ian Zhang as president and managing director of its Chinese operations. Zhang is the former head of Asia Pacific integration at Life Technologies and has also worked at Invitrogen.
